Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: DQ Entertainment, Tristel, ReNeuron

Tue, 03rd Apr 2012 12:39

DQ Entertainment, a producer of animation, visual effects, game art and live action entertainment content for the global media and entertainment industry, has won three new contracts for co-production. The first is with French broadcaster TF1 for the new 3D animated TV series of Robin Hood, the second is with Minika ATV for its new kids network in Turkey and the third is with Gaurmont Alphanim for the new 3D animated CGI TV series "Lanfeust". Tristel, a manufacturer of infection control, contamination control and hygiene products, has terminated its supply arrangement with Medichem International for disinfectants and cleaning products. Tristel will now directly market these products to veterinary practices, hospitals under Tristel related brands. Tristel is now free to address the veterinary market directly and to broaden its product offering within areas that it had not been directly involved with, including its core hospital marketplace. ReNeuron Group, a UK-based stem cell company, has announced a firm placing to raise up to £9.4m before expenses with the shares being sold at 4p each. The issue price represents a discount of around 21.2% to the mid-market closing price of 5.075p on the day before the placing was announced. In addition, investors in the placing are being issued warrants to subscribe for ordinary shares, which could raise up to another £8.1m for the company, before expenses, if the warrants are exercised. The company also said that to date no adverse reactions had been seen in the five stroke patients who have been administered with its ReN001 stem cell therapy treatment. The company expects to be able to apply for a phase II study next year. NR
More News

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.